Gufic Biosciences September profit rises 57% to Rs 23.49 crore

Gufic Biosciences Limited reported standalone profit after tax of Rs 23.49 crore for the quarter ended September 30, 2026, up 57% from Rs 14.94 crore a year earlier, as revenue from operations increased 25% to Rs 288.40 crore. Gufic Biosciences also reported half-year profit of Rs 45.95 crore.

How did Gufic Biosciences perform in the September quarter?

Gufic Biosciences earned standalone profit after tax of Rs 23.49 crore in the quarter ended September 30, 2026, compared with Rs 14.94 crore in the quarter ended September 30, 2025. The increase was 57% based on the reported figures, while profit was also above Rs 22.46 crore recorded in the quarter ended June 30, 2026.

Revenue from operations was Rs 288.40 crore, against Rs 230.42 crore a year earlier and Rs 260.82 crore in the preceding June quarter. This represented 25% year-on-year growth and an approximately 11% sequential increase. Gufic Biosciences identifies pharmaceuticals as its single operating segment, so the filing does not provide revenue by product category or business unit.

Profit before tax rose to Rs 31.49 crore from Rs 20.53 crore, while total tax expense increased to Rs 8.00 crore from Rs 5.59 crore. Basic and diluted earnings per share were both Rs 2.34, compared with Rs 1.49 in the September 2025 quarter. Paid-up equity share capital remained Rs 10.03 crore, with a face value of Rs 1 per share.

What changed in Gufic Biosciences' costs and income?

Gufic Biosciences reported a Rs 57.02 crore year-on-year rise in total income to Rs 289.53 crore during the September 2026 quarter, while total expenses increased by Rs 46.05 crore to Rs 258.03 crore. The resulting increase in profit before tax was Rs 10.96 crore, before tax expense rose by Rs 2.41 crore.

Cost of materials consumed rose to Rs 156.92 crore from Rs 113.47 crore in the September 2025 quarter. Employee-benefit expense increased to Rs 10.44 crore from Rs 9.32 crore, while other expenses were Rs 58.98 crore against Rs 57.27 crore. Depreciation and amortisation was Rs 7.73 crore, compared with Rs 7.77 crore a year earlier.

Finance cost was Rs 19.76 crore in the September 2026 quarter, compared with Rs 9.58 crore in the prior-year quarter. Other income declined to Rs 1.12 crore from Rs 2.09 crore. Gufic Biosciences reported no exceptional items in either quarter, leaving the reported profit-before-tax comparison unaffected by an exceptional-item line.

How did Gufic Biosciences perform in the first half?

Gufic Biosciences reported standalone profit after tax of Rs 45.95 crore for the half year ended September 30, 2026, compared with Rs 27.01 crore in the corresponding six months of 2025. The increase was approximately 70%, with the September quarter contributing Rs 23.49 crore and the June quarter contributing Rs 22.46 crore.

Revenue from operations for the half year rose to Rs 549.22 crore from Rs 457.33 crore in the corresponding prior-year period. Total income increased to Rs 550.80 crore from Rs 460.31 crore, while profit before tax rose to Rs 61.65 crore from Rs 36.81 crore. Total tax expense was Rs 15.71 crore, against Rs 9.80 crore a year earlier.

The half-year figures show that profit growth exceeded the 20% increase in revenue from operations. Finance cost for the six months was Rs 29.08 crore, compared with Rs 18.82 crore in the corresponding prior-year half, while cost of materials consumed rose to Rs 263.07 crore from Rs 201.99 crore. The results were prepared under Indian Accounting Standards, known as Ind AS.

What changed in Gufic Biosciences' cash flow and balance sheet?

Gufic Biosciences generated standalone net cash from operating activities of Rs 5.34 crore in the half year ended September 30, 2026, down from Rs 59.04 crore a year earlier. Operating profit before working-capital movements increased to Rs 95.85 crore from Rs 70.29 crore, but working-capital movements used Rs 78.72 crore, compared with an outflow of Rs 4.44 crore in the prior-year half.

The working-capital movement included a Rs 47.61 crore increase in inventories and a Rs 30.07 crore increase in trade and other receivables. Net cash used in investing activities was Rs 42.81 crore, compared with Rs 15.35 crore in the preceding year, including Rs 35.95 crore spent on property, plant and equipment including capital advances.

Standalone cash and cash equivalents stood at Rs 63.54 crore on September 30, 2026, compared with Rs 60.32 crore on March 31, 2026. Total assets rose to Rs 1,450.48 crore from Rs 1,341.59 crore, including capital work-in-progress of Rs 52.48 crore versus Rs 22.14 crore. Current borrowings increased to Rs 357.19 crore from Rs 280.13 crore, while non-current borrowings declined to Rs 92.26 crore from Rs 105.04 crore.

What else did Gufic Biosciences' November board meeting approve?

Gufic Biosciences' board approved the unaudited standalone and consolidated results on November 14, 2026, after review by the Audit Committee. The statutory auditors carried out a limited review of the results for the quarter and half year ended September 30, 2026, under the applicable listing requirements.

The board also approved the appointment of Dr. Reeta Shah as an additional non-executive independent director for a first term of five consecutive years from December 1, 2026, subject to shareholder approval. The board meeting began at 5:00 p.m. and concluded at 6:35 p.m. on November 14, 2026.

Conclusion

Gufic Biosciences recorded higher standalone revenue, profit before tax and profit after tax in both the September 2026 quarter and the first half ended September 30, 2026. The rise in quarterly profit to Rs 23.49 crore exceeded revenue growth, although finance costs, inventories, receivables and current borrowings were also higher than in the relevant comparison periods.

The next disclosed event is Dr. Reeta Shah's planned December 1, 2026 appointment, which remains subject to shareholder approval. Subsequent financial disclosures will show whether the movements in inventories, receivables, capital work-in-progress and current borrowings reported as of September 30, 2026 continue or change.